Please login to the form below
morphosys
This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.
Pfizer abandons antibody for Duchenne
Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this
Latest news
-
Daily brief: Novartis spends big on ezcema,
Novartis eczema deal worth up to $1bn for biotechs. MorphoSys and Galapagos have signed a major new deal with Novartis on their atopic dermatitis candidate MOR106, an IL-17c antibody. ... The deal adds to MorphoSys’momentum, as it launched its listing
-
Roche starts new late-stage trials of Alzheimer’s candidate
In the interim, Roche and partner MorphoSys - which applied its antibody-generating technology to the creation of the drug - have been carrying out safety studies to ensure that hiking exposure to ... 2020. The decision to press ahead with the phase III
-
Janssen’s Tremfya cleared for European use
Tremfya, an anti-IL-23 monoclonal antibody, was developed using MorphoSys ’HuCAL antibody library technology, allowing the German biotech to collect royalties on Tremfya sales under a multiple target deal it ... Dr Simon Moroney, chief executive officer
-
Lilly and Boehringer combine breast cancer drugs in trial
BI 836845 is one of the drugs that has emerged from the company's long-standing antibody collaboration with MorphoSys, and is also being tested in combination with Novartis' Femara (exemestane)
-
Pfizer signs high-level deal with GPCR specialist Heptares
It also has collaborations in place with AstraZeneca (AZ), Merck &Co's Cubist unit, MorphoSys and Takeda.
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
-
Pharma deals in March 2015
In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
-
Deal Watch table for August 2014
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
-
Pharma deals during August 2014
These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.
-
Pharma deals during June 2014
Joining the checkpoint modulator fray, Merck Serono formed a partnership with Morphosys to discover and develop antibodies against certain immune checkpoints using the Morphosys Ylanthia platform.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Industry round up: appointments
Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Dave Lemus joins Proteros as an executive board member
He has also held roles with MorphoSys and Hoffman La Roche.
-
MorphoSys appoints Dr Markus Enzelberger as CSO
MorphoSys appoints Dr Markus Enzelberger as CSO. He succeeds Dr Marlies Sproll who resigns. ... German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation.
-
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team. She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
Featured jobs
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Senior Medical Writer
-
Salary is DOE
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
-
Account Manager
-
Negotiable
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Healthcare PR Senior Account Manager
-
Salary TBC
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Associate Scientific Director
-
Salary TBC
-
Systematic Review Lead- London
-
Negotiable
Subscribe to our email news alerts
- Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications
- Innovate UK supports AI drug discovery project worth £1m
- Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications
- Superhuman editor wins promotion at Porterhouse Medical
- Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
- Biotech leaders jump into US free speech debate
PMHub
infill healthcare communication
infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
